SLC6A6 and acute myeloid leukemia: While SLC6A6 is broadly expressed in AML irrespective of karyotype or FAB subtype (TCGA; Extended Data Fig. 8b), increased expression correlates with venetoclax resistance (BEAT-AML; Fig. 4a).